Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 20 - Sep 25
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone
Avoid repeated exposure to heat, humidity, or direct light during handling
Many people with gallstones never experience symptoms, and the metabolic improvements from significant weight lossincluding better glycaemic control, reduced cardiovascular risk, and improved liver functionmay justify proceeding with treatment under close monitoring
This creates an unusual situation: ARA-290 has Phase 2 clinical data of reasonable quality, regulatory designations that recognized its therapeutic promise, and a well-characterized mechanism with a solid scientific foundation but no ongoing clinical development program or path to approval
